Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases

<b>Objective:</b>To compare the efficacy and adverse effects of paclitaxel-etoposide-carboplatin/cisplatin (TEP/TCE) regimen with those of etoposide-carboplatin/cisplatin (EP/CE) regimen as first-line treatment for combined small-cell lung cancer (CSCLC).<br/><b>Methods:</...

Full description

Bibliographic Details
Main Authors: Yue-Ya Li, Chan Zhou, Deng-Xia Yang, Jing Wang, Zhu-Jun Liu, Xin-Yue Wang, Kai Li
Format: Article
Language:English
Published: China Anti-Cancer Association 2015-06-01
Series:Cancer Biology & Medicine
Subjects:
Small cell lung carcinoma (SCLC)
chemotherapy
CE regimen
adverse effects
survival analysis
prognosis
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/848

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/848

Similar Items